BVB808 (NVP_BVB808) is a selective JAK2 inhibitor with approximately 10-fold selectivity for JAK2 over other JAK family members (such as JAK1 , JAK3 or TYK2 ) in vitro. BVB808 inhibits the activity of JAK2 and reduces the phosphorylation of STAT5 , thereby blocking the JAK2 -dependent cell proliferation and survival signaling pathways. BVB808 can be used in cancer research.